Pharmacy Daily | ACMS to consider kava use

THE use of the narcotic kava (Piper methysticum) may be exempted from scheduling controls when “used in accordance with the traditional patterns of the Pacific Island region,” under a proposal to be considered at the upcoming meeting of the Advisory Committee on Medicines Scheduling. Public submissions are being sought on a number of items for the meeting, including a proposal to list adrenaline in Appendix H and the possible rescheduling of azelastine to Schedule 2 when supplied in topical eye preparations. Topical preparations containing diclofenac may also be exempted from scheduling under another agenda item, while there’s a proposal to reschedule 1500mg or less of famciclovir from S4 to S3 when in oral preparations for the single dose treatment of cold sores. Public comment is also being sought on the scheduling of follistatin and fingolimod, as well as a proposal to amend S8 labelling requirements which could allow some common packaging to be used for S8 products in Australia and NZ - see www.tga.gov.au.

---

The above article was sent to subscribers in Pharmacy Daily's issue from 10 Aug 11
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 10 Aug 11